<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>From Retinal Pixels to Patients: Evolution of Deep Learning Research in Diabetic Retinopathy Screening - Health AI Hub</title>
    <meta name="description" content="This paper offers the first systematic synthesis of deep learning research in Diabetic Retinopathy (DR) screening from 2016-2025, consolidating insights from ov">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>From Retinal Pixels to Patients: Evolution of Deep Learning Research in Diabetic Retinopathy Screening</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.11065v1" target="_blank">2511.11065v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-14
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Muskaan Chopra, Lorenz Sparrenberg, Armin Berger, Sarthak Khanna, Jan H. Terheyden, Rafet Sifa
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.CV, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.11065v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.11065v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper offers the first systematic synthesis of deep learning research in Diabetic Retinopathy (DR) screening from 2016-2025, consolidating insights from over 50 studies and 20 datasets. It details the evolution of AI methodologies from basic CNNs to advanced pipelines addressing real-world challenges like data scarcity and domain shift, while outlining a practical agenda for clinically deployable DR AI.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Diabetic Retinopathy is a leading cause of preventable blindness, and this research is critical for advancing AI-driven early detection, which can significantly reduce vision loss globally. By focusing on deployable and trustworthy AI, it directly impacts patient outcomes and public health strategies for DR screening.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application is the development and deployment of deep learning models for automated screening and early detection of Diabetic Retinopathy from retinal images, aiming to reduce vision loss and improve healthcare access and efficiency in DR management.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Provides a systematic synthesis of deep learning advancements in DR screening over the past decade (2016-2025).</li>
                    
                    <li>Traces the evolution of AI methodologies from early convolutional neural networks to advanced techniques like self-/semi-supervised learning, domain generalization, and federated training.</li>
                    
                    <li>Highlights key challenges addressed by modern DR AI, including class imbalance, label scarcity, domain shift, and interpretability.</li>
                    
                    <li>Critically examines current evaluation protocols, reporting standards, and reproducibility challenges within the field.</li>
                    
                    <li>Contextualizes model performance across various datasets using benchmark tables.</li>
                    
                    <li>Identifies significant open gaps in multi-center validation and establishing clinical trust as barriers to widespread adoption.</li>
                    
                    <li>Proposes a practical agenda focused on developing reproducible, privacy-preserving, and clinically deployable DR AI solutions.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>This paper is a comprehensive systematic survey and synthesis of existing research. It consolidates findings from over 50 deep learning studies in Diabetic Retinopathy screening across more than 20 datasets. The authors critically examine methodological advancements, evaluation protocols, reporting standards, and reproducibility challenges, utilizing benchmark tables to contextualize performance.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>Deep learning in DR screening has matured from simple CNNs to sophisticated pipelines adept at handling data scarcity, domain shifts, and interpretability demands. While technical progress is substantial, the field faces significant hurdles in achieving robust multi-center validation and gaining sufficient clinical trust for widespread deployment. Inconsistent evaluation protocols and reporting standards contribute to reproducibility issues.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research aims to accelerate the translation of AI technology into clinical practice for early DR detection. By addressing challenges like privacy, reproducibility, and trustworthiness, it paves the way for efficient, accurate, and widespread screening programs, particularly benefiting underserved populations and potentially preventing vision loss for millions of patients through timely intervention.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The paper explicitly highlights existing 'open gaps in multi-center validation and clinical trust' as critical limitations within the current landscape of DR AI research, which hinder the translation of promising models into real-world clinical deployment.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The paper outlines a 'practical agenda' for future research, emphasizing the need for: robust multi-center validation studies, strategies to build clinical trust, improved reproducibility in research and reporting, further innovation in privacy-preserving AI (e.g., federated training), and continued development of interpretable and hybrid neuro-symbolic models.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Ophthalmology</span>
                    
                    <span class="tag">Endocrinology</span>
                    
                    <span class="tag">Public Health</span>
                    
                    <span class="tag">Preventative Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Diabetic Retinopathy</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">AI</span>
                    
                    <span class="tag tag-keyword">Medical Imaging</span>
                    
                    <span class="tag tag-keyword">Screening</span>
                    
                    <span class="tag tag-keyword">Retinal Imaging</span>
                    
                    <span class="tag tag-keyword">Computer Vision</span>
                    
                    <span class="tag tag-keyword">Preventable Blindness</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Diabetic Retinopathy (DR) remains a leading cause of preventable blindness, with early detection critical for reducing vision loss worldwide. Over the past decade, deep learning has transformed DR screening, progressing from early convolutional neural networks trained on private datasets to advanced pipelines addressing class imbalance, label scarcity, domain shift, and interpretability. This survey provides the first systematic synthesis of DR research spanning 2016-2025, consolidating results from 50+ studies and over 20 datasets. We critically examine methodological advances, including self- and semi-supervised learning, domain generalization, federated training, and hybrid neuro-symbolic models, alongside evaluation protocols, reporting standards, and reproducibility challenges. Benchmark tables contextualize performance across datasets, while discussion highlights open gaps in multi-center validation and clinical trust. By linking technical progress with translational barriers, this work outlines a practical agenda for reproducible, privacy-preserving, and clinically deployable DR AI. Beyond DR, many of the surveyed innovations extend broadly to medical imaging at scale.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>Accepted in IEEE BigData 2025</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>